At this point, if you enroll in the trial, you are

Quote:

---

At this point, if you enroll in the trial, you are agreeing to forego any other options for a time period.

---

Quote:

---

This is a Phase 3, 2-arm, randomized, double blind, placebo controlled, multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) as an add on therapy to the institutional standard of care (SoC) for the management of critically ill patients with COVID-19 pneumonia.
https://clinicaltrials.gov/ct2/show/NCT049016...amp;rank=3

---